Alessandro Zerbi

Summary

Affiliation: San Raffaele Scientific Institute
Country: Italy

Publications

  1. doi Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases
    Alessandro Zerbi
    Department of Surgery, Pancreas Unit, San Raffaele Scientific Institute, Milan, Italy
    Am J Gastroenterol 105:1421-9. 2010
  2. doi Pancreatic metastasis from renal cell carcinoma: which patients benefit from surgical resection?
    Alessandro Zerbi
    Pancreas Unit, Department of Surgery, S Raffaele Scientific Institute, V Olgettina 60, 20132, Milan, Italy
    Ann Surg Oncol 15:1161-8. 2008
  3. doi Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial
    Michele Reni
    Department of Oncology, S Raffaele Scientific Institute, Milan, Italy
    Ann Surg Oncol 19:2256-63. 2012
  4. doi Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases
    Alessandro Zerbi
    Pancreatic Surgery Section, Humanitas Scientific Institute, Via Manzoni 56, Rozzano, Milan, Italy
    Langenbecks Arch Surg 396:313-21. 2011
  5. ncbi Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma
    Michele Reni
    Department of Radiochemotherapy, S Raffaele H Scientific Institute, Milan, Italy
    Oncology 68:239-45. 2005
  6. doi Surgical management of insulinomas: short- and long-term outcomes after enucleations and pancreatic resections
    Stefano Crippa
    Department of Surgery, Chirurgia Generale B, Policlinico GB Rossi, University of Verona, Piazzale LA Scuro, 10 37134, Verona, Italy
    Arch Surg 147:261-6. 2012
  7. ncbi A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile
    Paolo Monti
    Laboratory of Experimental Surgery, Department of Diabetes and Transplant Immunology, S Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Virchows Arch 445:236-47. 2004
  8. doi Efficacy of an absorbable fibrin sealant patch (TachoSil) after distal pancreatectomy: a multicenter, randomized, controlled trial
    Marco Montorsi
    Department of General Surgery, University of Milan, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, Rozzano, Milan, Italy
    Ann Surg 256:853-9; discussion 859-60. 2012
  9. ncbi Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4
    Federica Marchesi
    Department of Immunology and Cell Biology, Mario Negri Institute, Milan, Italy
    Cancer Res 64:8420-7. 2004
  10. doi Extending indications for islet autotransplantation in pancreatic surgery
    Gianpaolo Balzano
    Department of Surgery, San Raffaele Scientific Institute, Milan, Italy
    Ann Surg 258:210-8. 2013

Detail Information

Publications31

  1. doi Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases
    Alessandro Zerbi
    Department of Surgery, Pancreas Unit, San Raffaele Scientific Institute, Milan, Italy
    Am J Gastroenterol 105:1421-9. 2010
    ..The aim of the study was to describe the clinical and pathological features of PETs in a prospective, multicenter study...
  2. doi Pancreatic metastasis from renal cell carcinoma: which patients benefit from surgical resection?
    Alessandro Zerbi
    Pancreas Unit, Department of Surgery, S Raffaele Scientific Institute, V Olgettina 60, 20132, Milan, Italy
    Ann Surg Oncol 15:1161-8. 2008
    ..Pancreas is a possible site of metastases from renal cell carcinoma (RCC). The aim of this study was to define the role of surgery in their treatment...
  3. doi Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial
    Michele Reni
    Department of Oncology, S Raffaele Scientific Institute, Milan, Italy
    Ann Surg Oncol 19:2256-63. 2012
    ..This randomized phase II trial aimed to identify the most promising regimen warranting phase III evaluation...
  4. doi Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases
    Alessandro Zerbi
    Pancreatic Surgery Section, Humanitas Scientific Institute, Via Manzoni 56, Rozzano, Milan, Italy
    Langenbecks Arch Surg 396:313-21. 2011
    ..Information on the treatment of pancreatic endocrine tumours (PETs) comes mostly from small, retrospective, uncontrolled studies...
  5. ncbi Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma
    Michele Reni
    Department of Radiochemotherapy, S Raffaele H Scientific Institute, Milan, Italy
    Oncology 68:239-45. 2005
    ..Postoperative management of patients with pancreatic adenocarcinoma (PA) is controversial...
  6. doi Surgical management of insulinomas: short- and long-term outcomes after enucleations and pancreatic resections
    Stefano Crippa
    Department of Surgery, Chirurgia Generale B, Policlinico GB Rossi, University of Verona, Piazzale LA Scuro, 10 37134, Verona, Italy
    Arch Surg 147:261-6. 2012
    ..To analyze the characteristics and outcomes following enucleation and pancreatic resections of insulinomas...
  7. ncbi A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile
    Paolo Monti
    Laboratory of Experimental Surgery, Department of Diabetes and Transplant Immunology, S Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Virchows Arch 445:236-47. 2004
    ..In conclusion, a clear correlation between structural/genetic features and function could not be detected, suggesting the weakness of a "morphological" classification for the in vitro studies of pancreatic cancer...
  8. doi Efficacy of an absorbable fibrin sealant patch (TachoSil) after distal pancreatectomy: a multicenter, randomized, controlled trial
    Marco Montorsi
    Department of General Surgery, University of Milan, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, Rozzano, Milan, Italy
    Ann Surg 256:853-9; discussion 859-60. 2012
    ..To evaluate the role of an absorbable fibrin sealant patch (TachoSil) in reducing postoperative pancreatic fistula (POPF) after distal pancreatectomy (DP)...
  9. ncbi Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4
    Federica Marchesi
    Department of Immunology and Cell Biology, Mario Negri Institute, Milan, Italy
    Cancer Res 64:8420-7. 2004
    ..CXCR4 not only stimulates cell motility and invasion but also promotes survival and proliferation. Strategies to target CXCR4 expressed on tumor cells may be of benefit in patients with pancreatic cancer...
  10. doi Extending indications for islet autotransplantation in pancreatic surgery
    Gianpaolo Balzano
    Department of Surgery, San Raffaele Scientific Institute, Milan, Italy
    Ann Surg 258:210-8. 2013
    ..To assess metabolic and oncologic outcomes of islet autotransplantation (IAT) in patients undergoing pancreatic surgery for either benign or malignant disease...
  11. doi Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma
    Michele Reni
    Department of Oncology, S Raffaele Scientific Institute, Milan, Italy
    Cancer 115:2630-9. 2009
    ..The objective of this study was to evaluate the correlation between a decline in carbohydrate antigen 19-9 (CA 19-9) and survival in patients with advanced pancreatic cancer who received upfront chemotherapy...
  12. doi Effect of surgeon volume on outcome following pancreaticoduodenectomy in a high-volume hospital
    Nicolò Pecorelli
    Department of Surgery, San Raffaele Hospital, Vita Salute San Raffaele University, Via Olgettina 60, 20132, Milan, Italy
    J Gastrointest Surg 16:518-23. 2012
    ..The aim of this study is to assess the independent impact of surgeon volume on outcome after PD in a single high-volume institution...
  13. doi Intraoperative ultrasound with contrast medium in resective pancreatic surgery: a pilot study
    Antonino Spinelli
    Unità Operativa e Cattedra di Chirurgia Generale, Universita degli Studi di Milano, Istituto Clinico Humanitas IRCCS, Via Alessandro Manzoni 56, 20089, Rozzano, Milan, Italy
    World J Surg 35:2521-7. 2011
    ..The purpose of the present study was to prospectively evaluate the possible role of contrast-enhanced intraoperative ultrasound (CEIOUS) during resective pancreatic surgery for primary lesion characterization and intraoperative staging...
  14. doi Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors
    Massimo Falconi
    Chirurgia Generale B Pancreas Unit, Department of Surgery, University of Verona, Policlinico GB Rossi, Verona, Italy
    Ann Surg Oncol 17:1621-7. 2010
    ..The aim of this study was to evaluate perioperative and long-term outcomes after PPRs for NF-PETs...
  15. pmc Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study
    Alessandro Zerbi
    Pancreatic Surgery, Department of Surgery, Humanitas Clinical and Research Center, Milan, Italy
    HPB (Oxford) 15:935-43. 2013
    ..The aim of this prospective, multicentre study was to assess treatment and outcomes of malignant pNENs in clinical practice...
  16. pmc Surgical management of acute pancreatitis in Italy: lessons from a prospective multicentre study
    Paolo De Rai
    Department of Surgery and Emergency Surgery, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Institute for Scientific Care and Treatment Ca Granda Ospedale Maggiore Policlinico, Milan, Italy
    HPB (Oxford) 12:597-604. 2010
    ..This study aimed to evaluate the surgical treatment of acute pancreatitis in Italy and to assess compliance with international guidelines...
  17. ncbi Intraductal papillary mucinous tumors of the pancreas: incidence, clinical findings and natural history
    Gianpaolo Balzano
    Pancreas Unit, Department of Surgery, S Raffaele Hospital, Milan, Italy
    JOP 6:108-11. 2005
  18. ncbi The unsolved problem of fistula after left pancreatectomy: the benefit of cautious drain management
    Gianpaolo Balzano
    Pancreas Unit, Department of Surgery, San Raffaele Milan, Italy
    J Gastrointest Surg 9:837-42. 2005
    ..7%). In conclusion, fistula is an unsolved problem of left pancreatectomy. However, a careful drain management allows a good outcome in patients with fistula...
  19. ncbi What is the role of pancreas units today?
    Valerio Di Carlo
    Department of Surgery, University Vita Salute, San Raffaele Hospital, Milan Italy
    JOP 7:101-3. 2006
    ..We think that the adoption of a Pancreas Unit model could represent the right answer to the recent changes observed in Medicine and could offer a better approach to patients with pancreatic diseases...
  20. pmc Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma
    Luigi Laghi
    Laboratory of Molecular Gastroenterology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
    PLoS ONE 7:e46002. 2012
    ..Aims of the study were to determine the prevalence of MSI in surgically resected pancreatic cancers in a multicentric, retrospective study, and to assess the occurrence of pancreatic cancer in LS...
  21. doi Cytological Ki-67 in pancreatic endocrine tumours: an opportunity for pre-operative grading
    Cecilia Piani
    General Medicine, Diabetes and Endocrinology Unit, San Raffaele Scientific Institute, Universita Vita Salute San Raffaele, Via Olgettina 60, Milano, Italy
    Endocr Relat Cancer 15:175-81. 2008
    ..65, 95% CI: 0.3, 0.9). Ki-67 expression measured on cytological samples obtained by EUS-FNAC before surgery showed good agreement with that measured on histological samples...
  22. ncbi Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell
    Paolo Monti
    Laboratory of Experimental Surgery, Surgical Department, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    J Immunol 172:7341-9. 2004
    ..These findings identify mucin secretion as a novel mechanism of tumor escape from immune surveillance and provide the basis for the generation of potentially tolerogenic DC...
  23. ncbi Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial
    Michele Reni
    Department of Radiochemotherapy, S Raffaele H Scientific Institute, Milan, Italy
    Lancet Oncol 6:369-76. 2005
    ..We aimed to assess whether a four-drug regimen could improve 4 month progression-free survival compared with gemcitabine alone...
  24. ncbi Strategies for tumor immune escape
    Lorenzo Piemonti
    Laboratory of Experimental Surgery, Department of Surgery II, Fondazione Centro S Raffaele del Monte Tabor, Milan, Italy
    Drugs Today (Barc) 39:701-24. 2003
    ..The purpose of this review is to evaluate the current status of knowledge concerning these different tumor-escape strategies...
  25. ncbi Antitumorigenic and antiinsulinogenic effects of calcitriol on insulinoma cells and solid beta-cell tumors
    Francesca Galbiati
    Department of Medicine, San Raffaele Scientific Institute, Milan 20132, Italy
    Endocrinology 143:4018-30. 2002
    ..Together, these findings provide the rationale for testing the efficacy of calcitriol in the treatment of patients with solid beta-cell tumors...
  26. ncbi Double self-expandable total-coated metal stent for gastrojejunal leak after pancreatoduodenectomy
    Enzo Masci
    Division of Gastroenterology and Gastrointestinal Endoscopy, Vita Salute San Raffaele University, Scientific Institute San Raffaele, Milan, Italy
    Gastrointest Endosc 66:1024-5. 2007
  27. ncbi Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma
    Marco Del Chiaro
    Regional Referral Center for Pancreatic Diseases Treatment, University of Pisa, Pisa, Italy
    Pancreatology 7:459-69. 2007
    ..Our aims were to examine familial aggregations of pancreas and other cancers, and to determine the relative risk of the family members...
  28. pmc Occlusion of the pancreatic duct versus pancreaticojejunostomy: a prospective randomized trial
    Khe Tran
    Departments of General Surgery, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Ann Surg 236:422-8; discussion 428. 2002
    ..Using a prospective randomized study to assess postoperative morbidity and pancreatic function after pancreaticoduodenectomy with pancreaticojejunostomy and duct occlusion without pancreaticojejunostomy...
  29. ncbi Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers
    Luigi Laghi
    Division of Gastroenterology, Istituto Clinico Humanitas, Rozzano, Milan, 20089 Italy
    Oncogene 21:4301-6. 2002
    ..Results show that multiple K-RAS mutations are frequent both in PC with associated PanIN and in biliary cancers, and indicate that clonally distinct precursor lesions of PC might variably contribute to tumor development...
  30. ncbi Spleen-preserving distal pancreatectomy with excision of splenic artery and vein: a cautionary note
    Gianpaolo Balzano
    World J Surg 31:1530; author reply 1531. 2007
  31. ncbi The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity
    Paolo Monti
    Laboratory of Experimental Surgery, Department of Surgery II, Fondazione Centro S Raffaele del Monte Tabor, Via Olgettina 60, 20132 Milan, Italy
    Cancer Res 63:7451-61. 2003
    ..On the whole, the results presented in our investigation suggest that CCL2 could be a relevant negative regulator of pancreatic cancer progression...